FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.
IPO Year:
Exchange: NASDAQ
Website: fsdpharma.com
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K/A - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
SC 13D/A - FSD Pharma Inc. (0001771885) (Subject)
SC 13D - FSD Pharma Inc. (0001771885) (Subject)
SC 13D/A - FSD Pharma Inc. (0001771885) (Subject)
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), announced today that the Company and Dr. Raza Bokhari, Company's former Executive Chairman and Chief Executive Officer (CEO), have reached a global settlement agreement (the "agreement") to settle all and any disputes originating out of the proxy contest originally commencing January 2021. Mr. Zeeshan Saeed, Co-Chairman & CEO, and Mr. Anthony Durkacz, Co-Chairman of the Company, also signed the agreement in their personal capacity. The agreement brings to a complete and final closure all outstanding issues and prevents any future litigation in var
TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal for Ontario was dismissed entirely in favour of Quantum BioPharma. Dr. Raza Bokhari, current CEO of Medicus Pharma, Ltd., was CEO of FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) now Qu
Awards in favour of Quantum BioPharma Total Approximately $3 Million TORONTO, ON / ACCESS Newswire / January 17, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it will be back in the Ontario Superior Court of Justice on January 24, 2025. Quantum BioPharma is seeking a Court Order declaring Dr. Raza Bokhari, current CEO of Medicus Pharma,
TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e
TORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.Changes in ManagementEffective August 30, 2024, Donal Carroll will assume the role of Chief Financial Officer and Nathan Coyle will assume the role of Controller. In addition, the Company has appointed Jason Sawyer as the Head of Finance and Mergers and Acquisitions for the Company.Option CancellationEffective today, the Company has cancelled an aggregate of 32,690 o
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption.On August 9, 2024, Celly Nutrition which is backed by a world-class pharmaceutical research & development team at FSD Pharma, operated by CEO John Duffy, formerly of Coca-Cola, and co-chaired by Gerry David the former CEO of Celsius Holdings (CELH) proudly announces the imminent launch of its revolutionary, great tasting and scientifically bac
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.Corporate UpdateFSD Pharma has retained the services of Totaligent, Inc. ("Totaligent") who will play a key role in assisting the Company to enhance its market awareness and foster productive, continuing dialogues with shareholders and other market participants. Totalaligent has over 25 years of experience in market awareness campaigns and has assembled a database of 32 million active investors and reaches its in
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows:USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.CAD $31,912.55, plus interest at a rate of 4%
TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatmen
TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it entered into an exclusive option agreement with the University of Southern California (USC) to evaluate dietary supplement technology for commercialization. The option agreement, signed June 11, 2024, allows FSD Pharma to exclusively evaluate the novel technology for a 6-month term. At the end of this term, FSD Pharma will have the option to either extend it for an additional 6 months or to sign an exclusive
BALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on FSD Pharma, Inc. (NASDAQ:HUGE)(CSE:HUGE), an innovative biopharmaceutical firm with one product slated for commercialization in 1Q24 and a unique treatment for MS preparing a Phase II clinical trial for 2H24 The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit https://bit.ly/3Rer5Av.FSD Pharma is a biopharmaceutical company building a portfolio of innovative
TORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that the FSD Pharma Securityholders (defined below) have approved the previously-announced plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") pursuant to which common shares in the capital of Celly Nutrition Corp. ("Celly Nu"), will be distributed to the holders of class A multiple voting shares ("Class A Shares"), class B subordinate voting shares ("Class B Shares"), and holders of warra
TORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that, further to its press release dated November 7, 2023, that its distribution date for the contemplated plan of arrangement (the "Arrangement") is November 29, 2023 (the "Distribution Date"). Subject to the satisfaction of all applicable closing conditions of the Arrangement, common shares in the capital of Celly Nutrition Corp. ("Celly Nu Shares") will be distributed to FSD Pharma Securityholders (as defined below) of record as of No
TORONTO, ON / ACCESSWIRE / November 7, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to announce that the company, in the upcoming weeks will be announcing the record date for the Company's special dividend of shares of Celly Nutrition Corp. ("Celly Nu"), the holder of exclusive rights to FSD Pharma's revolutionary recreational alcohol misuse technology. Led by beverage and marketing icons, Celly Nu is actively developing a first-in-class product that has been shown to effectively expedite alcohol metabolism. In the coming weeks share
TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e
TORONTO, ON / ACCESSWIRE / January 29, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce the appointment of Dr. Sanjiv Chopra to its board of directors. Dr. Chopra will be replacing Nitin Kaushal, who has resigned from his position on the board. FSD Pharma thanks Mr. Kaushal for his contribution and wishes him well on his future endeavours.Dr. Sanjiv ChopraDr. Sanjiv Chopra, MD, is Professor of Medicine and served as Faculty Dean for Continuing Medical Education at Harvard Medical School for 12 years. He serves as a Marshall W
TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to announce that it has provided certain additional disclosure, by way of a Supplement dated November 15, 2023 (the "Supplement") to its Management Information Circular dated October 20, 2023 (the "Circular"), relating to certain restrictions on resale that will apply to the Celly Nu Shares that will be distributed to the FSD Pharma Securityholders. Capitalized terms not defined in this news release have the meanings assigned in the Circular.FSD Phar
Appointment culminates multi-year succession plan as FSD focuses on commercialization of its UNBUZZD™ alcohol misuse product and Lucid-MS for neurodegenerative disorders FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announces appointment of Zeeshan Saeed as Chief Executive Officer ("CEO") of the Company. Mr. Saeed, a Co-Founder of FSD Pharma who has held the position of President since 2019, was elected CEO via unanimous vote at a meeting of the Board
Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company's Advisory Board. "Mr. Allan and Dr. McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to our team," commented Anthony Durkacz, Foun
Regulatory Advisory Board will oversee the drug development pathway for FSD Pharma's clinical drug candidates FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has formed a Regulatory Advisory Board ("RAB") and has appointed Joga Gobburu, B.Pharm. (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. A world-recognized scientific leader in pharmacometrics, Dr. Gobburu is a Professor at the School of Pharmacy and the School of Medicine, University of Maryland, Baltimore, MD. Between 1998 and 2011, he held va
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board. Dr. Fish, an accomplished researcher in the areas of immunology and inflammatory disorders, and member of the Government of Canada's Expert Scientific Panel to the Chief Scientific Advisor, brings key expertise to FSD Pharma that will support the continued development of FSD-PEA, the Company's proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis. "I
Appoints Anthony Durkacz as Interim Chief Executive Officer and Reinstates Zeeshan Saeed as President FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") announced today that the board of directors had terminated the employment of the Company's Chief Executive Officer, Dr. Raza Bokhari for cause. As previously disclosed by the Company, Dr. Bokhari was placed on administrative leave following the Company's shareholder meeting on May 14, 2021 while a special committee (the "Special Committee") comprised of two independent directors investigated various concerns regarding Dr. Bokhari's actions in his capacity as the Company's Chief Executive Officer. The Special Commi
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) is pleased to announce the appointment of Mr. Adnan Bashir as an independent member of its Board of Directors (the “Board”), upon the recommendation of the Company’s Compensation, Nomination and Governance Committee. As previously announced, Mr. Frank Lavelle was elected to the Board at the Company’s annual general and special meeting of shareholders held on May 14th, 2021 (the “Meeting”). Shortly after the Meeting, Mr. Lavelle communicated his resignation to the Board, leaving a vacancy, and Mr. Bashir has been appointed to fill that vacancy. The Board considers Mr. Bashir to b
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") is pleased to announce the appointment of Mr. Adnan Bashir as an independent member of its Board of Directors (the "Board"), upon the recommendation of the Company's Compensation, Nomination and Governance Committee. As previously announced, Mr. Frank Lavelle was elected to the Board at the Company's annual general and special meeting of shareholders held on May 14th, 2021 (the "Meeting"). Shortly after the Meeting, Mr. Lavelle communicated his resignation to the Board, leaving a vacancy, and Mr. Bashir has been appointed to fill that vacancy. The Board considers Mr. Bashir to be "independent" within the meaning of